Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 1, 2014, Pages 106-115

  Desai, Rajeev I ^a   Grandy, David K ^c   Lupica, Carl R ^b   Katz, Jonathan L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; CANNABINOID 1 RECEPTOR; COCAINE; COCAINE ANTAGONIST; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; DOPAMINE TRANSPORTER LIGAND; DRUGS USED IN THE TREATMENT OF ADDICTION; JHW 007; N (N BUTYL) 3ALPHA [BIS(4 FLUOROPHENYL)METHOXY]TROPANE; N [2 (3,4 DICHLOROPHENYL)ETHYL] N METHYL 2 (1 PYRROLIDINYL)ETHYLAMINE; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; STEREOTYPY;

ANIMALS; BENZTROPINE; COCAINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY;

EID: 84891642078     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.208538     Document Type: Article

References (33)

1. Agoston GE, Wu JH, Izenwasser S, George C, Katz J, Kline RH, and Newman AH (1997) Novel N-substituted 3 alpha-[bis(49-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter. J Med Chem 40:4329-4339.
2. Campbell VC, Kopajtic TA, Newman AH, and Katz JL (2005) Assessment of the influence of histaminergic actions on cocaine-like effects of 3alphadiphenylmethoxytropane analogs. J Pharmacol Exp Ther 315:631-640.
3. Chausmer AL, Elmer GI, Rubinstein M, Low MJ, Grandy DK, and Katz JL (2002) Cocaine-induced locomotor activity and cocaine discrimination in dopamine D2 receptor mutant mice. Psychopharmacology (Berl) 163:54-61.
4. Desai RI and Terry P (2003) Evidence of cross-tolerance between behavioural effects of nicotine and cocaine in mice. Psychopharmacology (Berl) 166:111-119.
5. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, and Katz JL (2005a) Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25:1889-1893.
6. Desai RI, Kopajtic TA, French D, Newman AH, and Katz JL (2005b) Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-2-[bis-(4-fluorophenyl)methoxy] ethyl-4-(3-phenylpropyl) piperazine], and benztropine analogs. J Pharmacol Exp Ther 315:397-404.
7. Hiranita T, Soto PL, Newman AH, and Katz JL (2009) Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther 329: 677-686.
8. Hiranita T, Kohut SJ, Soto PL, Tanda G, Kopajtic TA, and Katz JL (2013) Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats. J Pharmacol Exp Ther doi: 10.1124/jpet.113.208264 [Epub Ahead of Print].
9. Jutkiewicz EM, Eller EB, Folk JE, Rice KC, Traynor JR, and Woods JH (2004) Deltaopioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J Pharmacol Exp Ther 309:173-181.
10. Katz JL, Izenwasser S, Kline RH, Allen AC, and Newman AH (1999) Novel 3adiphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. J Pharmacol Exp Ther 288:302-315.
11. Katz JL, Kopajtic TA, Agoston GE, and Newman AH (2004) Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J Pharmacol Exp Ther 309:650-660.
12. Katz JL, Su TP, Hiranita T, Hayashi T, Tanda G, Kopajtic T, and Tsai SY (2011) A role for sigma receptors in stimulant self administration and addiction. Pharmaceuticals (Basel) 4:880-914.
13. Kopajtic TA, Liu Y, Surratt CK, Donovan DM, Newman AH, and Katz JL (2010) Dopamine transporter-dependent and-independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability. J Pharmacol Exp Ther 335:703-714.
14. Lever JR, Scheffel U, Stathis M, Seltzman HH, Wyrick CD, Abraham P, Parham K, Thomas BF, Boja JW, and Kuhar MJ, et al. (1996) Synthesis and in vivo studies of a selective ligand for the dopamine transporter: 3 b-(4-[125I]iodophenyl) tropan-2 b-carboxylic acid isopropyl ester ([125I]RTI-121). Nucl Med Biol 23:277-284.
15. Li SM, Newman AH, and Katz JL (2005) Place conditioning and locomotor effects of N-substituted, 49,40-difluorobenztropine analogs in rats. J Pharmacol Exp Ther 313:1223-1230.
16. Li SM, Kopajtic TA, O'Callaghan MJ, Agoston GE, Cao J, Newman AH, and Katz JL (2011) N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects. J Pharmacol Exp Ther 336:575-585.
17. Li L, Hiranita T, Hayashi S, Newman AH, and Katz JL (2013) The stereotypyinducing effects of N-substituted benztropine analogs alone and in combination with cocaine do not account for their blockade of cocaine self-administration. Psychopharmacology (Berl) 225:733-742.
18. Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, Sitte HH, Newman AH, Katz JL, and Gether U (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73:813-823.
19. Matsumoto RR (2009) Targeting sigma receptors: novel medication development for drug abuse and addiction. Expert Rev Clin Pharmacol 2:351-358.
20. Mello NK and Negus SS (1996) Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14:375-424.
21. Menkel M, Terry P, Pontecorvo M, Katz JL, and Witkin JM (1991) Selective sigma ligands block stimulant effects of cocaine. Eur J Pharmacol 201:251-252.
22. Navarro HA, Howard JL, Pollard GT, and Carroll FI (2009) Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol 156:1178-1184.
23. Raje S, Cao J, Newman AH, Gao H, and Eddington ND (2003) Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J Pharmacol Exp Ther 307:801-808.
24. Scheffel U, Boja JW, and Kuhar MJ (1989) Cocaine receptors: in vivo labeling with 3H-(-)cocaine, 3H-WIN 35,065-2, and 3H-WIN 35,428. Synapse 4:390-392.
25. Scheffel U, Pögün S, Stathis M, Boja JW, and Kuhar MJ (1991) In vivo labeling of cocaine binding sites on dopamine transporters with [3H]WIN 35,428. J Pharmacol Exp Ther 257:954-958.
26. Scheffel U, Dannals RF, Wong DF, Yokoi F, Carroll FI, and Kuhar MJ (1992) Dopamine transporter imaging with novel, selective cocaine analogs. Neuroreport 3: 969-972.
27. Tanda G, Kopajtic TA, and Katz JL (2008) Cocaine-like neurochemical effects of antihistaminic medications. J Neurochem 106:147-157.
28. Tanda G, Newman AH, and Katz JL (2009a) Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. Adv Pharmacol 57:253-289.
29. Tanda G, Newman AH, Ebbs AL, Tronci V, Green JL, Tallarida RJ, and Katz JL (2009b) Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity. J Pharmacol Exp Ther 330:802-809.
30. Tanda G, Li SM, Mereu M, Thomas AM, Ebbs AL, Chun LE, Tronci V, Green JL, Zou MF, and Kopajtic TA, et al. (2013) Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change. Psychopharmacology (Berl) 229:307-321.
31. Velázquez-Sánchez C, Ferragud A, Hernández-Rabaza V, Nácher A, Merino V, Cardá M, Murga J, and Canales JJ (2009) The dopamine uptake inhibitor 3 alpha-[bis(49-fluorophenyl)metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward. Neuropsychopharmacology 34: 2497-2507.
32. Velázquez-Sánchez C, Ferragud A, Murga J, Cardá M, and Canales JJ (2010) The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization. Eur Neuropsychopharmacol 20:501-508.
33. Vocci FJ, Acri J, and Elkashef A (2005) Medication development for addictive disorders: the state of the science. Am J Psychiatry 162:1432-1440.